Trial site
Complejo Asistencial de Zamora. Hospital Provincial de Zamora
Zamora, 49020, SpainNot linked to an institution yet
- 12running trials
- 6closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 23 trials
- Phase 2/33 trials
- Phase 11 trial
- Status
- Recruiting8 trials
- Completed6 trials
- Active, not recruiting2 trials
- Not yet recruiting2 trials
- Lead sponsor
- ACADIA Pharmaceuticals Inc.2 trials
- Intra-Cellular Therapies, Inc.2 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- AB Science1 trial
- Boehringer Ingelheim International GmbH1 trial
- and 10 more
Running trials
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Not yet recruiting
Masitinib in Patients With Mild Alzheimer's Disease
NCT05564169· Phase 3· AB Science· Source
Contact: Clinical Study Coordinator
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· Phase 2/3· Exciva GmbH· Source
Active, not recruiting
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· Phase 3· Newron Pharmaceuticals S.p.A.· Source
Recruiting
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
NCT07655115· Phase 3· Hospital General Universitario Gregorio Marañon· Source
Recruiting
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source
Active, not recruiting
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression
2023-505268-12-00· Phase 3· Compass Pathfinder Limited· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Recruiting
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source
Recruiting
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· Phase 2· Oryzon Genomics S.A.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error